Journal of
eISSN: 2572-8466
Submit manuscript...
Review Article Volume 12 Issue 4
Cystic fibrosis: therapeutic developments and market trends within the broader landscape of lung disease
Sophie Naddour, Tawil Bill
Received: July 21, 2025 | Published: August 12, 2025
Citation: Naddour S, Bill T. Cystic fibrosis: therapeutic developments and market trends within the broader landscape of lung disease. J Appl Biotechnol Bioeng. 2025;12(4):168-178. DOI: 10.15406/jabb.2025.12.00399
Abstract
The paper examines the CF therapeutic market, recent trends, and CF research pipelines, focusing on this rare genetic disorder primarily affecting the lungs. The first part sharpens the definition of CF as a chronic pulmonary disease, explores the physical changes involved, looks at its distributional pattern, and discusses the effects of CF on people’s survival. The market analysis includes the market size, differences among countries or regions, and what future trends are likely to happen. Treatments, including CFTR modulators and add-on therapies, are paid for, plus new advances like gene editing and those using mRNA, ENaC inhibitors, and microbiome targeting. There is a special emphasis on both mutation-specific and mutation-agnostic approaches during the development of clinical and preclinical products. Regulations and policies for gaining drug approval and for patients to access these drugs are addressed, along with incentives for orphan drugs and difficulties with reimbursement. The essay also looks at the current barriers to equal access, lower costs, and global fairness in healthcare. It ends by highlighting the impact of involving technology and individual medicine, which can transform treatment for all CF patients worldwide.
Keywords: cystic fibrosis (CF), CFTR modulators, gene therapy, orphan drug policy, global healthcare access, personalized medicine
©2025 Naddour, et al. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.